CytoSorbents reports Q3 EPS (21c), consensus (12c)

Reports Q3 revenue $8.81M, consensus $9.49M. Phillip Chan, CEO of CytoSorbents stated, “Our core business is built upon our E.U. approved flagship CytoSorb(R) blood purification therapy, used in more than 221,000 human treatments with more than $205 million in sales to date, including $31.4 million in the last 12 months alone. CytoSorb addresses multi-billion dollar markets in critical care and cardiac surgery in 75 countries worldwide by treating deadly inflammation and other life-threatening conditions. These are common everyday ICU conditions like sepsis, trauma, burn injury, respiratory failure, liver failure, and complications of surgery where mortality is high despite standard therapies. With the world struggling in the aftermath of the pandemic with war, natural disasters, and illness, we believe our life-saving therapy has never been more relevant.”